Anti-addl antibodies and uses thereof

Details Anti-addl antibodies and uses thereof Anti-addl antibodies and uses thereof

2005-10-21

2010-10-12

Kolker, Daniel E. (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C530S387300, C435S007200, C424S141100

Reexamination Certificate

active

07811563

ABSTRACT:
The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

REFERENCES:
patent: 6218506 (2001-04-01), Krafft et al.
patent: 6743427 (2004-06-01), Schenk
patent: 6750324 (2004-06-01), Schenk et al.
patent: 6761888 (2004-07-01), Schenk
patent: 6787637 (2004-09-01), Schenk
patent: 6797492 (2004-09-01), Daugherty et al.
patent: 6913745 (2005-07-01), Schenk
patent: 2003/0068316 (2003-04-01), Klein et al.
patent: WO 97/11971 (1997-04-01), None
patent: WO 03/104437 (2003-12-01), None
patent: WO 2005/025516 (2005-03-01), None
U.S. Appl. No. 60/621,776, filed Oct. 25, 2004.
U.S. Appl. No. 60/652,538, filed Feb. 14, 2005.
U.S. Appl. No. 60/695,526, filed Jun. 30, 2005.
U.S. Appl. No. 60/695,528, filed Jun. 30, 2005.
Armour et al., “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities”, Eur. J. Immuno. 1999 29:2613.
Birmingham, K. and Frantz, S., “Set back to Alzheimer vaccine studies”, Nat. Med. 2002 8:199-200.
Bitan et al., “Neurotoxic protein oligomers-what you see is not always what you get”, Amyloid 2005 12(2):88-95.
Canfield and Morrison, “The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and is Modulated by the Hinge Region”, J. Exp. Med. 1991 173:1483-1491.
Chang et al., “Femtomole Immunodetection of Synthetic and Endogenous Amyloid-β Oligomers and its Application to Alzheimer's Disease Drug Candidate Screening”, J. Molecular Neuroscience 2003 20:305-313.
Dodart et al., “Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model”, Nat. Neurosci. 2002 5:452-457.
Gong et al., “Alzheimer's disease-affected brain:Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss”, Proc. Natl. Acad. Sci. USA 2003 100:10417-10422.
Hardy et al., “The Amyloid Hypothesis of Alzheimer's Disease:Progress and Problems on the Road to Therapeutics”, Science 2002 297:353-356.
Hock et al., “Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease”, Neuron 2003 38:547-554.
Hougs et al., “The first constant-domain (CH1) exon of humanIGHG2is polymorphic and in strong linkage disequilibrium with the CHW exon polymorphism encoding the G2m(n+) allotype in Caucasians”, Immunogenetics 2001 52:242-248.
Ida et al., “Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and blood by a Newly Developed Sensitive Western Blot Assay”, J. Biol. Chem. 1996 271(37) :22903-22914.
Kayed et al., “Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis”, Science 2003 300:486-489.
Klein, William L., “Aβ toxicity in Alzheimer's disease:globular oligomers (ADDLs) as new vaccine and drug targets”, Neurochemistry International 2002 41:345-352.
Kotilnek et al., “Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease”, J. Neurosci 2002 22:6331-6335.
Lambert et al., “Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies”, J. Neurochemistry 2001 79:595-605.
Lambert et al., “Diffusible, nonfibrillar ligands derived from Aβ1-42are potent central nervous system neurotoxins”, Proc. Natl. Acad. Sci. USA 1998 95:6448-6453.
Lathe, R., “Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data-Theoretical and Practical Considerations”, J. Mol. Biol. 1985 183:1-12.
Lu et al., “A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor”, Nat. Med. 2000 6:397-404.
Medgyesi et al., “Functional mapping of the FcγRll binding site on human IgGl by synthetic peptides”, Eur. J. Immunol. 2004 34:1127-1135.
Padlan, Eduardo A., “Anatomy of the Antibody Molecule”, Molecular Immunology 1994 31(3):169-217.
Tao et al., “The Differential Ability of Human IgG1 and IgG4 to Activate Complement is Determined by the COOH-terminal Sequence of the CH2 Domain”, J. Exp. Med. 1991 173:1025-1028.
Xu et al., “Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement”, J. Biol. Chem 1994 269:3469-3474.
Zuckier et al., “The Use of Severe Combined Immunodeficiency Mice to Study the Metabolism of Human Immunoglobulin G”, Cancer Suppl. 1994 73:794-799.
Terry et al., “Physical Basis of Cognitive Alterations in Alzheimer's Disease:Synapse Loss is the Major Correlate of Cognitive Impairment”, 1991 Ann. Neurol. 30:572-580.
Coyle et al., “Alzheimer's Disease”, 1987 In:Encyclopedia of Neuroscience, Adelman (ed.), Birkhäser, Boston-Basel-Stuttgart, pp. 29-31.
Selkoe et al., “Alzheimer's Disease is a Synaptic Failure”, 2002 Sciecne 298:789-791.
Katzman et al., “Clinical, Pathological, and Neurochemical Changes in Dementia:A Subgroup with Preserved Mental Status and Numerous Neocortical Plaques”, 1988 Ann. Neurol. 23:138-144.
Frantz et al. , “Set back to Alzheimer vaccine studies”, 2002 Nat. Med. 8:199-200.

Affiliated with

Also associated with

Rating

Anti-addl antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-addl antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-addl antibodies and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4194664